# UK Innovation & Science Seed Fund

> UK Innovation & Science Seed Fund is a VC fund backing Biotechnology. See 144 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Harwell, United Kingdom
- Total investments: 144
- Last investment: Jul 2026
- Lead investor: 32%
- Last fund: Aug 2014
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/rainbow-seed-fund
- X (Twitter): https://twitter.com/uki2s
- Website: https://ukinnovationscienceseedfund.co.uk

UK Innovation & Science Seed Fund is a VC fund in Harwell focused on Biotechnology and Health Care. The UK Innovation & Science Seed Fund is backed by the Department for Business, Energy and Industrial Strategy and the Fund’s partners are 9 publicly funded research bodies, including STFC, BBSRC, NERC and Dstl. The Fund is independently managed by venture capital specialist Midven.They help build companies from great science developed inlaboratories, science and technology campuses and synthetic biology.They hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.

## Contacts

5 contacts available for UK Innovation & Science Seed Fund. Shizune tracks 4 team members at UK Innovation & Science Seed Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/rainbow-seed-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $458k–$5.9M |
| Series A | $2.9M–$14M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 39 | 27% |
| Health Care | 21 | 15% |
| Medical | 17 | 12% |
| Manufacturing | 14 | 10% |
| Software | 13 | 9% |

84 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 67 | 47% |
| Funding Round | 16 | 11% |
| Series A | 6 | 4% |
| Grant | 4 | 3% |
| Pre-Seed | 3 | 2% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 79 | 55% |
| United States | 3 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexander Leigh | Investment Director | 13 | https://shizune.co/investors/profile/alexander-leigh |
| Andrew Muir | Investment Director & Fund Principal | 8 | https://shizune.co/investors/profile/andrew-muir |
| Mark White | Director | 4 | https://shizune.co/investors/profile/mark-white-6 |
| Oliver Sexton | Investment Director | 17 | https://shizune.co/investors/profile/oliver-sexton |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Halo X Ray Technologies | HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. |  | Corporate Round | Jul 20, 2026 |  |
| Halo X Ray Technologies | HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. |  | Venture - Series Unknown | Jul 20, 2026 |  |
| Silicon MicroGravity | Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK. | $8.1M | Venture - Series Unknown | Jul 16, 2026 |  |
| Luffy AI | Luffy AI uses Adaptive Intelligence to evolve robotic control systems. | $10.8M | Series A | Jul 07, 2026 |  |
| Revolver Therapeutics | Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K | Pre-Seed | Jul 03, 2026 |  |
| Silveray | Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market. | $6.6M | Series A | Jun 17, 2026 |  |
| Hexigone Inhibitors | Hexigone aims to replace toxic chemicals used in the anti-corrosion market with our disruptive, novel, micro/nano reservoir technologies, creating 'smart' coatings. Our additives will enable the coatings to protect for longer in an intelligent manner, increasing the lifetime cycle of the end product, reducing the drain on primaryresources. | $1.6M | Seed | Jun 02, 2026 |  |
| QuberTech | QuberTech develops biotechnology solutions to create an alternative natural rubber supply chain. The company engineers dandelion crops using precision breeding and gene editing to increase latex production in their roots to commercially viable levels. It integrates these crop innovations with soil-free, controlled-environment aeroponic farmingsystems designed for industrial rubber production. QuberTech focuses on controlled indoor cultivation to reduce exposure to climate and disease risks associated with traditional plantations. Its technology targets early applications in sectors that use high-specification natural rubber, including medical products, footwear, and fashion. The company also participates in collaborative research and development programmes such as the QuBOOSTR consortium to advance its platform toward commercial-scale facilities. | $4.6M | Seed | May 20, 2026 |  |
| Spaceflux | Spaceflux is a UK-based seed-stage company founded in 2022 with the aim of tackling the problem of space congestion in view of rising satellite deployment. Leveraging on our proprietary optical sensor network and a unique, AI-driven analytics platform, we provide unparalleled tracking and mapping services for space objects. Our dynamic analyticscan offer actionable insights about objects’ characteristics and behaviors derived from static image data. Catering primarily to satellite operators, governments, and the insurance industry, our goal is to reduce congestion and create a safer space environment. We are driven by an exceptional team and thrive on innovation. | $4.7M | Seed | Apr 27, 2026 |  |
| Ascension | Ascension develops geothermal-based technologies for critical mineral recovery. | $1.4M | Seed | Apr 15, 2026 |  |

10 of 144 investments shown.

## Co-investors
- [Future Planet Capital](https://shizune.co/investors/profile/future-planet-capital) — VC Fund, 30 deals together
- [Longwall Venture](https://shizune.co/investors/profile/longwall-venture-partners) — VC Fund, 9 deals together
- [Oxford Technology Management](https://shizune.co/investors/profile/oxford-technology-management) — VC Fund, 9 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 8 deals together
- [ACF Investors](https://shizune.co/investors/profile/angel-cofund) — VC Fund, 7 deals together
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [All Investors in United Kingdom](https://shizune.co/investors/investors-united-kingdom)
- [All VC Funds in United Kingdom](https://shizune.co/investors/vc-funds-united-kingdom)
- [Transportation Investors in United Kingdom](https://shizune.co/investors/transportation-investors-united-kingdom)
- [Transportation VC Funds in United Kingdom](https://shizune.co/investors/transportation-vc-funds-united-kingdom)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)

## FAQ

### What does UK Innovation & Science Seed Fund invest in?

UK Innovation & Science Seed Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Funding Round stage. Most of the 144 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is UK Innovation & Science Seed Fund's check size?

UK Innovation & Science Seed Fund typically joins rounds of $458k–$5.9M at Seed and $2.9M–$14M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds UK Innovation & Science Seed Fund participates in.

### How do I contact UK Innovation & Science Seed Fund?

Public channels for UK Innovation & Science Seed Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at UK Innovation & Science Seed Fund?

The team at UK Innovation & Science Seed Fund includes Alexander Leigh (Investment Director), Andrew Muir (Investment Director & Fund Principal) and Mark White (Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co